1. Canellos GP. Residual mass in lymphoma may not be residual disease. J Clin Oncol. 1988;6(6):931–3.
2. Naumann R, Vaic A, Beuthien-Baumann B, Bredow J, Kropp J, Kittner T, et al. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin’s disease and non-Hodgkin’s lymphoma. Br J Haematol. 2001;115(4):793–800.
3. Radford JA, Cowan RA, Flanagan M, Dunn G, Crowther D, Johnson RJ, et al. The significance of residual mediastinal abnormality on the chest radiograph following treatment for Hodgkin’s disease. J Clin Oncol. 1988;6(6):940–6.
4. Surbone A, Longo DL, Devita VT, Ihde DC Jr, Duffey PL, Jaffe ES, et al. Residual abdominal masses in aggressive non-Hodgkin’s lymphoma after combination chemotherapy: significance and management. J Clin Oncol. 1988;6(12):1832–7.
5. Adams HJA, Kwee TC. Proportion of false-positive lesions at interim and end-of-treatment FDG-PET in lymphoma as determined by histology: systematic review and meta-analysis. Eur J Radiol. 2016;85(11):1963–70.